 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- Rituxan (rituximab) / Roche, Biogen, TJC4 - I / Mab
TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5798;
Conclusion In summary, TJC4 is a next generation therapeutic anti-CD47 antibody that is devoid of the hematological liabilities while maintaining anti-tumor efficacy. These attributes of TJC4 differentiate it from other CD47 targeting agents currently in clinical evaluation.
- | lemzoparlimab (ABBV-IMAB-TJC4) - I / Mab
Enrollment open, Metastases: KEYNOTE-A21: Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma (clinicaltrials.gov) - May 14, 2019
P1, N=88, Recruiting, Sponsor: I-Mab Biopharma Co. Ltd.
These attributes of TJC4 differentiate it from other CD47 targeting agents currently in clinical evaluation. Not yet recruiting --> Recruiting
- | lemzoparlimab (ABBV-IMAB-TJC4) - I / Mab
New P1 trial, Metastases: KEYNOTE-A21: Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma (clinicaltrials.gov) - May 1, 2019
P1, N=88, Not yet recruiting, Sponsor: I-Mab Biopharma Co. Ltd.